

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

Volume 63

Published online July 26, 2021

Online  
Only  
Article

### IN THIS ISSUE

In Brief: Risdiplam (*Evrystdi*) for Spinal Muscular Atrophy

## Important Copyright Message

### FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)  
or call customer service at: 800-211-2769

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

Volume 63

Published online July 26, 2021

Online  
Only  
Article

### IN THIS ISSUE

In Brief: Risdiplam (*Evrystdi*) for Spinal Muscular Atrophy

### IN BRIEF

## Risdiplam (*Evrystdi*) for Spinal Muscular Atrophy

Risdiplam (*Evrystdi* – Genentech), a survival of motor neuron 2 (SMN2) splicing modifier, has been approved by the FDA for oral treatment of spinal muscular atrophy (SMA) in patients  $\geq 2$  months old. It is the first oral drug to be approved in the US for treatment of SMA; nusinersen (*Spinraza*), an intrathecally administered SMN2-directed antisense oligonucleotide, and onasemnogene abeparvovec (*Zolgensma*), an IV adeno-associated virus vector-based gene therapy, were approved earlier.<sup>1,2</sup>

#### Pronunciation Key

Risdiplam: ris dip' lam

*Evrystdi*: ev riz' dee

**THE DISORDER** – SMA is an autosomal recessive disorder in which degeneration of alpha motor neurons in the anterior horn cells of the spinal cord leads to muscle weakness and atrophy. It occurs in about one in every 10,000 births.<sup>3</sup> Most cases of SMA are caused by a homozygous deletion or mutation in the 5q13 SMN1 gene, which leads to SMN protein deficiency. The SMN2 gene also codes for SMN protein, but exon 7 is excluded during splicing, which results in low levels of functional SMN protein; the severity of disease is inversely correlated with the SMN2 copy number.<sup>4</sup>

**MECHANISM OF ACTION** – Risdiplam is an SMN2 splicing modifier. Like nusinersen, it acts by increasing exon 7 inclusion in SMN2 messenger RNA transcripts, which increases the gene's production of functional SMN protein in the CNS and peripheral tissues.<sup>5</sup>

**CLINICAL STUDIES** – FDA approval of risdiplam was based on the results of two clinical trials: an open-label trial (FIREFISH) in infants 2-7 months old (infantile-

onset; type 1 SMA) and a randomized, double-blind trial (SUNFISH) in patients 2-25 years old (later-onset SMA; type 2 or 3 SMA). Both trials consisted of two parts: a dose-finding study and an efficacy study.

In FIREFISH part 1 (results of part 2 have not been published to date), 4 infants were treated with a low dose (final dose of 0.08 mg/kg) of risdiplam and 17 were treated with the recommended dose (final dose of 0.2 mg/kg). Median SMN protein concentrations had increased from baseline by a median of 3.0 times in the low-dose group and by 1.9 times in the higher-dose group at 12 months. Seven patients in the higher-dose group and none in the low-dose group were able to sit without support for at least 5 seconds at 12 months.<sup>6</sup> Among infants treated with risdiplam for  $\geq 12$  months, 81% (17 out of 21) were alive without the need for permanent ventilation and reached  $\geq 28$  months of age.

In SUNFISH part 2, 180 non-ambulatory patients were randomized to receive risdiplam (at the FDA-approved dosage for age and weight) or placebo. At 12 months, significant improvements in motor function, including an increased level of independence in activities of daily living, occurred in more patients taking risdiplam than in those taking placebo. The change from baseline at 12 months in the motor function measure 32 (MFM32) score, with higher scores indicating greater motor function, was 1.36 with risdiplam and -0.19 with placebo, a statistically significant difference.<sup>7</sup>

Two open-label trials, one in patients 6-60 years old with SMA (JEWELFISH) and one in infants  $\leq 6$  weeks old with SMA (RAINBOWFISH), are ongoing.

**ADVERSE EFFECTS** – The most common adverse effects of risdiplam (occurring in  $\geq 5\%$  of patients and at higher rates than with placebo in SUNFISH part 2) were fever, diarrhea, rash, mouth and aphthous ulcers, arthralgia, and urinary tract infection. Irreversible

retinal degeneration was observed in animals exposed to higher concentrations of the drug than those used in FIREFISH and SUNFISH.

**DOSAGE, ADMINISTRATION, AND COST** – Risdiplam should be administered orally or via nasogastric or gastrostomy tube once daily after a meal. The recommended dosage is 0.2 mg/kg in patients 2 months–<2 years old, 0.25 mg/kg in those ≥2 years old weighing <20 kg, and 5 mg in those ≥2 years old weighing ≥20 kg. The cost of one year's treatment with *Evrysdi* is \$335,100.<sup>8</sup> ■

1. Nusinersen (Spinraza) for spinal muscular atrophy. *Med Lett Drugs Ther* 2017; 59:50.
2. Zolgensma – one-time gene therapy for spinal muscular atrophy. *Med Lett Drugs Ther* 2019; 61:113.
3. EA Sugarman et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical

laboratory analysis of >72,400 specimens. *Eur J Hum Genet* 2012; 20:27.

4. MA Farrar et al. Emerging therapies and challenges in spinal muscular atrophy. *Ann Neurol* 2017; 81:355.
5. A Poirier et al. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. *Pharmacol Res Perspect* 2018; 6:e00447.
6. G Baranello et al. Risdiplam in type 1 spinal muscular atrophy. *N Engl J Med* 2021; 384:915.
7. E Mercuri et al. SUNFISH part 2: efficacy and safety of risdiplam (RG7916) in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). *Neurology* 2020; 94(15 Suppl):1260.
8. Cost for a patient ≥2 years old weighing ≥20 kg. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. July 5, 2021. Reprinted with permission by First Databank, Inc. All rights reserved. ©2021. [www.fdbhealth.com/drug-pricing-policy](http://www.fdbhealth.com/drug-pricing-policy).

**PRESIDENT:** Mark Abramowicz, M.D.; **VICE PRESIDENT AND EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School  
**VICE PRESIDENT AND EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

**CONTRIBUTING EDITORS:** Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Franco M. Muggia, M.D., New York University Medical Center; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

**MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS:** Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

**FULFILLMENT AND SYSTEMS MANAGER:** Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli  
**EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS:** Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

#### Subscription Services

**Address:**  
 The Medical Letter, Inc.  
 145 Huguenot St. Ste. 312  
 New Rochelle, NY 10801-7537  
[www.medicalletter.org](http://www.medicalletter.org)

**Customer Service:**  
 Call: 800-211-2769 or 914-235-0500  
 Fax: 914-632-1733  
 E-mail: [custserv@medicalletter.org](mailto:custserv@medicalletter.org)

**Permissions:**  
 To reproduce any portion of this issue, please e-mail your request to: [permissions@medicalletter.org](mailto:permissions@medicalletter.org)

**Subscriptions (US):**  
 1 year - \$159; 2 years - \$298;  
 3 years - \$398. \$65 per year  
 for students, interns, residents,  
 and fellows in the US and Canada.  
 Reprints - \$45 per issue or article

**Site License Inquiries:**  
 E-mail: [SubQuote@medicalletter.org](mailto:SubQuote@medicalletter.org)  
 Call: 800-211-2769  
 Special rates available for bulk subscriptions.

Get Connected:  

Copyright 2021. ISSN 0025-732X

